Vol 6, No 3 (2009)

Articles
Metabolic syndrome as a prothrombogenic state
., .
Abstract
The prevalence of obesity has reached epidemic proportions nowadays. Abdominal obesity is the most unfavorable one, because of its association with the complex of markers and risk factors ofcardiovascular diseases and type 2 diabetes mellitus, which is called metabolic syndrome (MS). MS also increases risk of atherothrombosis because it is characterized by low fibrinolysis and prothrombogenic changes in coagulation and platelet hemostasis. The review highlights the mechanisms of hemostatic disturbances in MS, which eхends our scientific knowledge about pathogenesis of cardio vascular diseases
Obesity and metabolism. 2009;6(3):3-9
views
Potential opportunities for treatment of metabolic syndrome withalpha-lipoic acid (Berlithion®300)
., .
Abstract
There are a lot of experi mental data confirmed the influence of alpha-lipoi с acid on activity of AMPK enzyme, receptors PPARα/γ and uncoupling proteins that prev ent oxidative phosphorylation (UCPl). AMPK is the enzyme responsible for food intake and energy expenditure in hypothalamus as w ell as in peripheral adipose tissue. PPARγ is the key modulator of lipid ho meostasis and adipocyte differentiation. UCPl is located in the brown adipose tissue and provides termogenesis. Via regulation of mentioned biological targets alpha-lipoic acid (Berlithion®300) lowers insulinresistance, favors weight losing process and improvement of blood lipid profile.
Obesity and metabolism. 2009;6(3):10-14
views
Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
.
Abstract
Insulin resistance in muscle and liver and β-cell failure represent the core pathophysiologic defects in type 2 diabetes. Now it isrecognized that the β-cell failure occurs much earlier and is more severe than previously thought. As a result, earlier and more aggressive new therapy is needed to achiev e better control of diabetes and to prev ent/slow the progressive B-cell failure that already is w ell established in IGT subjects. One approach is to target the incretin mimetic hormone glucagon-like peptide-1 (GLP-1). When blood glucose levels are elevated, GrP-1 stimulates insulin secretion, decreases glucagon secretion, impro ves β-cell function, and slows gastric emptying. GrP-1 production is reduced in patients with type 2 diabetes. Furthermore, GrP-1 is rapidly degraded by the dipeptidyl peptidase 4 (DPP-4) enzyme. Trials have showed, that new inhibitor DPP-4 vildagliptin (Galvus) hav e been demonstrated to significantly reduce HbA lc, fasting and prandial glucose levels when used as monotherapy and in соmbination with traditional agents. Advantages of vildagliptin include few adverse events, low risk of hypoglycemia, neutral effect on body weight, and a once-daily oral dosing regimen. Inaddition, vildagliptin may preserve the decline in β-cell function. Hence, vildagliptin may modify the natural progressive course of diabetes; this however, must be confirmed with longer-term controlled studies
Obesity and metabolism. 2009;6(3):16-26
views
Metabolic abnormalities and behavioral peculiarities in patients with obesity: statics and dynamics on Orlistat therapy
., ., ., .
Abstract
Obesity causes variety of metabolic disorders, and decreases the quality of life. At the same time many people with BMI>30 kg/A possess different psychopathologic disturbances. The results of ourwork disclose high percentage of impaired carbohydrate metabolism, hyperlipidemia, and resistance to insulin in patients with obesity Besides, it was revealed that more than a half of the patients have symptoms of maladjustment, and decreased quality of life. Reduction of body w eight due to the treatment with Orlistat w as accompanied by improvement in parameters of carbohydrate and lipid metabolism and quality of life
Obesity and metabolism. 2009;6(3):27-38
views
Normogonadotropic hypogonadism in men with obesity
., ., ., .
Abstract
Objective: to evaluate the preavalence and characteristics of hypogonadism in obese man. Research and Methods: Thestudy was performed in 31 obese man (aged 33 [22;44], BMI 40 [34,4;44,0]. Measurements during the study: chemistry panel, testosteroa and LH levels, immunoreactive insulin, HOMA index calculation. Statistically significant difference w as considered as p < 0,05. Results. Hypogonadism preavalence was 80,6%. The hypogonadism prevalence and testosterone level was more depended on age and obesity but less on duration. 100 % risk of hypogonadism w as observed in heavily obese patients. There w as no increase of LH levels. In man with low testosterone lev els HOMA index w as significantly higher со mpared to healthy subjects. Conclusion: The prevalence of normogonadotropic hypogonadism in obese men is extremely high and it represents an evidence of functional disorder of hypophyseal gonadal system. Thedecrease of testosterone levels is age-coinciding, but it is more pronounced in obese nan.
Obesity and metabolism. 2009;6(3):39-42
views
The influence of parental metabolic state on development of psy-chovegetative syndrome in children
., ., .
Abstract
The influence of parental metabolic state on development of psychovegetative syndrome in children. The data from the present study which involved neuropsychological assessment shows significant deteriorations in immediate audio vocal, visial memory and attention in children with metabolic syndrome which have parents with type 2 diabetes mellitus
Obesity and metabolism. 2009;6(3):43-47
views
Pharmacoeconomic analysis of physiotens in patientswith arterial hypertension, overweight and type 2 diabetes mellitusin framework of Russian Public Health System
.
Abstract
The present article represent a pharmacoeconomic comparison of standard antihypertensive therapy and the same therapy plus moxonidine (Physiotens) in patients with arterial hypertension, overweight and diabetes mellitus type 2. The budget impact analysis was conducted on outpatient and inpatient care basis. Moxonidine showеd convincing advantages compared to standard antihypertensive therapy such as the stroke risk reduction by 6 percent, reduction of doses antihypertensive and hypoglycemic drugs, which resulted in substantial decrease of direct medical costs.
Obesity and metabolism. 2009;6(3):48-52
views
ACTH-ectopic syndrome in patient with lung carcinoid
., ., ., ., ., ., ., ., ., ., .
Abstract
ACTH-ectopic hypercortisolism is one of the most соmplex variants of endocrine pathology presenting with v arious metabolic changes. Its early localization still represents a cornerstone of radical treatment of such patients. In this article w e discuss a clinical case of woman with ectopic secretion of ACTH by malignant lung carcinoid, which localization and therefore surgical treatment wаs possible only after three-year period of extensive diagnostic workup.
Obesity and metabolism. 2009;6(3):54-58
views
Metformin - the gold standard in type 2 diabetes:what does the evidence tell us?
.
Abstract
Obesity and metabolism. 2009;6(3):59-61
views
The glucostatic theory of appetite controland the risk of obesity and diabetes
.
Abstract
Obesity and metabolism. 2009;6(3):63
views
Leptin, but not adiponectin, is a predictor of recurrentcardiovascular events in men: results from the LIPID study
.
Abstract
Obesity and metabolism. 2009;6(3):63-64
views
Early overweight and pubertal maturation - pathwaysof association with young adults' overweight:a longitudinal study
.
Abstract
Obesity and metabolism. 2009;6(3):65
views
Obesity and sexual dysfunction, male and female
.
Abstract
Obesity and metabolism. 2009;6(3):65-66
views
Is obesity associated with anemia of chronic disease? A population-based study
.
Abstract
Obesity and metabolism. 2009;6(3):66-67
views
Use of sibutramine hydrochloride monohydrate in the treatmentof the painful peripheral neuropathy of diabetes
.
Abstract
Obesity and metabolism. 2009;6(3):67-68
views
Adolescent and young adult vegetarianism: better dietary intakeand weight outcomes but increased risk of disordered eatingbehaviors
.
Abstract
Obesity and metabolism. 2009;6(3):70
views
Duration of lactation and risk factors for maternal cardiovascular disease
.
Abstract
Obesity and metabolism. 2009;6(3):71-72
views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies